  The paclitaxel-carboplatin doublet is an alternative choice in the first line treatment of metastatic or recurrent cervical cancer according to international guidelines. The history of seven patients treated with paclitaxel-platinum in the last three years in the Petz Alad√°r Hospital is reported. A case report , supporting the efficacy of the combination in emergency and in reintroduced settings is presented as well. The average progression-free survival was 10 months. All patients were alive at the time of the submission of the article. The results confirm the efficacy of the paclitaxel-carboplatin AUC 5 and the paclitaxel-cisplatin combinations in the treatment of metastatic cervical cancer. Orv Hetil. 2018; 159 ( 24): 974-977.